Business success in the life sciences: an investment banker's perspective

13 December 2016
2019_biotech_test_vial_discovery_big

Our firm recently opened a London-based European office. As we are passionate about bringing paradigm-shifting technologies to patients, we were excited by the opportunity to facilitate transatlantic collaborations between Boston’s biotech hub and the life sciences-rich Oxford/Cambridge/London ‘golden triangle’, writes Outcome Capital’s managing director Oded Ben-Joseph.

In preparation, we spent considerable time talking with biotech and pharma companies as well as academic research labs throughout the UK. Our aim was to get a more in-depth understanding of the local industry, its strengths, weaknesses and particular needs, as well as to look for technologies where we could provide strategic expertise in helping to capture their full value.

While the UK continues to generate exciting and potentially world-leading science, representing potential future ‘stars,’ we found that there remains a greater number of companies facing significant challenges in terms of successfully progressing technology to shareholder return.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology